Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs

Executive Summary

• Sharp Therapeutics announced it will advance an alternative compound into clinical development for its Gaucher disease and GBA1 Parkinson’s programs, replacing the earlier “901-series” candidate due to suboptimal dose proportionality in longer‑term non‑GLP studies.
• The company highlighted continued progress across its platform, including small‑molecule leads for Niemann‑Pick Type C and Progranulin modulation programs targeting a range of neurodegenerative disorders.
• Management emphasized the superior pharmaceutical properties of the new candidate and its potential to accelerate Phase I trials, underscoring significant therapeutic and commercial upside.

Key Details

• Program Decision: Replacement of “901-series” compound with a newly identified alternative that shows better physical properties, metabolic behavior, dose proportionality, oral availability, CNS penetration, and in‑vivo activity.
• Target Indications: Gaucher disease and GBA1‑associated Parkinson’s disease (GBA1‑PD).
• Scientific Rationale: New candidate restores GBA1 function via a novel mechanism; superior pharmacokinetics expected to improve clinical development timeline.
• Platform Continuity: Ongoing advancement of:
• Small‑molecule leads for Niemann‑Pick Type C that lower accumulated cholesterol in patient cells.
• Progranulin modulation program aimed at genetic and sporadic neurodegenerative diseases (Frontotemporal Dementia, Alzheimer’s, Parkinson’s).
• Management Quote: CEO/CSO Scott Sneddon, Ph.D., JD stated the decision reflects Sharp’s “high standard for advancing any therapeutic candidate into clinical development” and provides an opportunity to bring a higher‑quality compound into Phase I.
• Forward‑Looking Outlook: Company believes its platform approach could generate significant therapeutic and commercial opportunities; statements are forward‑looking and subject to risks and uncertainties.

Notable Quotes

“Advancing a compound with superior pharmaceutical properties provides the opportunity to bring the highest quality compound into Phase I development and eventually to patients.” – Scott Sneddon, Ph.D., JD, CEO/CSO, Sharp Therapeutics Corp.